Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide

被引:176
作者
Kreppel, Florian [1 ]
Kochanek, Stefan [1 ]
机构
[1] Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany
关键词
D O I
10.1038/sj.mt.6300321
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The chemical modification of adenovirus (Ad) gene transfer vectors with synthetic polymers is a promising strategy for overcoming typical in vivo hurdles associated with Ad-mediated gene delivery. Polymer-modified Ad vectors induce significantly reduced innate immune responses, can evade pre-existing anti-Ad antibodies, allow for repeated vector delivery, and have been used for developing novel retargeting strategies. The most widely used polymers for covalent chemical capsid surface modification are poly-N-(2-hydroxypropyl)methac rylamide (poly-HPMA) and polyethylene glycol (PEG), and the latter is in wide clinical use for modifying protein biopharmaceuticals. In this review, we critically compare the properties of various polymers with respect to Ad vector shielding and retargeting, and identify areas for future research on polymer-modified viral vectors. We describe the potential technical pitfalls of polymer modification of Ad vectors and provide a technical guide for avoiding these while establishing polymer modification techniques in the laboratory.
引用
收藏
页码:16 / 29
页数:14
相关论文
共 84 条
[1]   Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[2]   CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].
Alemany, R ;
Curiel, DT .
GENE THERAPY, 2001, 8 (17) :1347-1353
[3]   CHARACTERIZATION OF AN ADENOVIRUS GENE-TRANSFER VECTOR CONTAINING AN E4 DELETION [J].
ARMENTANO, D ;
SOOKDEO, CC ;
HEHIR, KM ;
GREGORY, RJ ;
STGEORGE, JA ;
PRINCE, GA ;
WADSWORTH, SC ;
SMITH, AE .
HUMAN GENE THERAPY, 1995, 6 (10) :1343-1353
[4]   The influence of blood on in vivo adenovirus bio-distribution and transduction [J].
Baker, Andrew H. ;
Mcvey, John H. ;
Waddington, Simon N. ;
Di Paolo, Nelson C. ;
Shayakhmetov, Dmitry M. .
MOLECULAR THERAPY, 2007, 15 (08) :1410-1416
[5]  
Beekman NJCM, 1997, J PEPT RES, V50, P357
[6]   Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates [J].
Brunetti-Pierri, N ;
Palmer, DJ ;
Beaudet, AL ;
Carey, KD ;
Finegold, M ;
Ng, P .
HUMAN GENE THERAPY, 2004, 15 (01) :35-46
[7]   Current advances and future challenges in adenoviral vector biology and targeting [J].
Campos, Samuel K. ;
Barry, Michael A. .
CURRENT GENE THERAPY, 2007, 7 (03) :189-204
[8]   Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting [J].
Campos, Samuel K. ;
Barry, Michael A. .
VIROLOGY, 2006, 349 (02) :453-462
[9]   Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response [J].
Christ, M ;
Lusky, M ;
Stoeckel, F ;
Dreyer, D ;
Dieterle, A ;
Michou, AI ;
Pavirani, A ;
Mehtali, M .
IMMUNOLOGY LETTERS, 1997, 57 (1-3) :19-25
[10]   PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile [J].
Croyle, MA ;
Le, HT ;
Linse, KD ;
Cerullo, V ;
Toietta, G ;
Beaudet, A ;
Pastore, L .
GENE THERAPY, 2005, 12 (07) :579-587